Hepatitis C virus and dendritic cells

Current Immunology Reviews

Volumn 2, Issue 4, 2006, Pages 305-312

  Agrawal, Babita ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Dendritic cells; Hepatitis C virus; Immune responses; T cells

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; HEPATITIS C VACCINE; INTERLEUKIN 10; PEGINTERFERON; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; CELL FUNCTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 33750699649     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/1573395510602040305     Document Type: Review

References (94)

1. Pohani G, Zou S, Tepper M. Trends of hepatitis B and hepatitis C mortality in Canada. Can J Public Health 2001; 92: 250-4.
2. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 5-14.
3. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
4. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524-8.
5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
6. Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature 2005; 436: 930-2.
7. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991-188: 5547-51.
8. Hijikata M, Mizushima H, Tanji Y, et al. Proteolytic processing and membrane association of putative nonstructural proeins of hepatitis C virus. Proc Natl Acad Sci USA 1993; 90: 10773-7.
9. Branch AD, Stump DD, Gutierrez JA, Eng F, Walewski JL. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis 2005; 25: 105-17.
10. Sansonno D, Iacobelli AR, Cornacchiulo V, Iodice G, Dammacco F. Detection of hepatitis C virus proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. Clin Exp Immunol 1996; 103: 414-21.
11. Zignego AL, De Carli M, Monti M, et al. Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol 1995; 47: 58-64.
12. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7.
13. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.
14. Koziel MJ. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat 1997; 4 (Suppl 2): 31-41.
15. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-8.
16. Koizumi K, Enomoto N, Kurosaki M, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22: 30-5.
17. Perry CM, Jarvis B. Spotlight on Peginterferon-alpha-1a (40 KD) in chronic Hepatitis C. BioDrugs 2002; 16: 213-7.
18. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
19. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
20. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus infection. Lancet 1998; 352: 1426-32.
21. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon a2b alone or in combination with ribavirin as initial treatment for chronic hepatitis. N Engl J Med 1998; 339: 1485-92.
22. Neumann AU, Zeuzem S, Ferrari C, et al. DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2-3 patients treated with PEG-interferon-alfa-2a and ribavirin. J Hepatol 2002; 36 (Suppl 1): 121.
23. Pawlotsky JM. Early HCV genotype 4 replication kinetics during treatment with peginterferon alpha-2b (Pegasys)-ribavirin combination: a comparison with HCV genotypes 1 and 3 kinetics. Hepatology 2002; 36: 283A.
24. Feld JJ and Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-972.
25. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-83.
26. Weiner AJ, Paliard X, Selby MJ, et al. Intrahepatic Genetic Inoculation of Hepatitis C Virus RNA Confers Cross-Protective Immunity. J Virol 2001; 75: 7142-48.
27. Bassett SE, Guerra B, Brasky K, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001; 33: 1479-87.
28. Lanford RE, Guerra B, Chavez D, et al. Cross-Genotype Immunity to Hepatitis C Virus. J Virol 2004; 78: 1575-81.
29. Kanto T, Hayashi N. Immunopathology of hepatitis C virus infection: Multifaceted strategies subverting innate and adaptive immunity. Intern Med 2006, 45: 183-91.
30. Koziel MJ. Immunology of viral hepatitis. Am J Med 1996; 100: 98-109.
31. Chang KM, Rehermann B, Chisari FV. Immunopathology of hepatitis C. Springer Semin Immunopathol 1997; 19: 57-68.
32. Chien DY, Choo QL, Ralston R, Spaete R, Tong M, Houghton M, Kuo G. Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet 1993; 342: 933.
33. Botarelli P, Brunetto MR, Minutello MA, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104(2): 580-7.
34. Ferrari C, Valli A, Galati L, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286-95.
35. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-14.
36. Lechmann M, Ihlenfeldt HG, Braunschweiger I, et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996; 24: 790-5.
37. +) T cells: implications for vaccine development. Hepatology 1999; 30: 1088-98.
38. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71: 6011-9.
39. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-tymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-7.
40. Meyer-Olson D, Shoukry NH, Brady KW, et al. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med 2004; 200: 307-19.
41. Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol 2004; 172: 483-92.
42. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
43. Missale G, Cariani E, Lamonaca V, et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997; 26: 792-7.
44. Lasarte JJ, Garcia-Granero M, Lopez A, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998; 28: 815-22.
45. Weston SJ, Leistikow, RL, Reddy KR, et al. Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation. Hepatology 2005; 41: 72-81.
46. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
47. Hiroishi K, Kita H, Kojima M, et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 1997; 25: 705-12.
48. Wong DK, Dudley DD, Afdhal NE, et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998; 160: 1479-88.
49. Rehermann B, Chang KM, McHutchinson J, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996; 70: 7092-102.
50. Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158: 1473-81.
51. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-49.
52. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-512.
53. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-82.
54. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176: 859-66.
55. Bronowicki JP, Vetter D, Uhl G, et al, Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients. J Infect Dis 1997; 176: 518-22.
56. Hiroishi K, Kita H, Kojima M, et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 1997; 25: 705-12.
57. Bassett SE, Guerra B, Brasky K, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001; 33: 1479-87.
58. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-7.
59. + T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002; 76: 12584-95.
60. + T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002; 35: 190-8.
61. Day CL, Seth NP, Lucas M, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003; 112: 831-42.
62. MacDonald AJ, Duffy M, Brady MT, et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis 2002; 185: 720-7.
63. +) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062-71.
64. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-62.
65. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-55.
66. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-45.
67. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R. T cell response in hepatitis C virus infection. J Clin Virol 2005; 32: 75-85.
68. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
69. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Immunol 2004; 58: 391-424.
70. Adams S, O'Neill DW, Bhardwaj N. Recent Advances in Dendritic Cell Biology. J Clin Immunol 2005; 25: 87-98.
71. Zuniga EI, McGavern DB, Pruneda-Paz JL, Teng C, Oldstone MB. Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection. Nat Immunol 2004; 5: 1227-34.
72. Coccia EM, Severa M, Giacomini E, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805.
73. Ito T, Wang YH, Liu YJ. Pplasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Springer Semin Immunopathol 2005; 26: 221-229.
74. Fonteneau JF, Larsson M, Bhardwaj N. Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr Opinion Immunol 2002; 4: 471-7.
75. Gett AV, Sallusto F, Lanzavecchia A, Geginat J. T cell fitness determined by signal strength. Nat Immunol 2003; 4: 355-60.
76. Gowans EJ, Jones KL, Bharadwaj M, Jackson DC. Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol 2004; 30: 283-90.
77. Matsui M, Moriya O, Abdel-Aziz N, Matsuura Y, Miyamura T, Akatsuka T. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine 2002; 21: 211-20.
78. Kanto T, Hayashi N, Takehara T, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162: 5584-91.
79. Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97: 3171-6.
80. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120: 512-24.
81. Pachiadakis I, Pollara G, Chain BM, Naoumov NV. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis 2005; 5: 296-304.
82. Lanford RE, Chavez D, Chisari FV, Sureau C. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol 1995; 69:8079-83.
83. Longman RS, Talal AH, Jacobson IM, Alberta ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 2004; 103:1026-1029.
84. Piccioli D, Tavarini S, Nuti S, et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 2005; 42: 61-7.
85. Yakushijin T, Kanto T, Inoue M, et al. Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection. Hepatol Res 2006 Feb 1; [Epub ahead of print]
86. Kanto T, Inoue M, Miyatake H, et al. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis 2004; 190: 1919-26.
87. Anthony DD, Yonkers NL, Post AB, et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol 2004; 172: 4907-16.
88. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 2005; 192: 497-503.
89. Larsson M, Babcock E, Grakoui A, et al. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol 2004; 78: 6151-61.
90. Rollier C, Drexhage JA, Verstrepen BE, et al. Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment. Hepatology 2003; 38: 851-8.
91. Lau AH, Thomson AW. Dendritic cells and immune regulation in the liver. Gut 2003; 52: 307-14.
92. Li W, Li J, Tyrrell DLJ, Agrawal B. Expression of hepatitis C virus-derived core or NS3 antigens in human dendritic cells leads to induction of proinflammatory cytokines and normal T-cell stimulation capabilities. J Gen Virol 2006; 87:61-72.
93. Sarobe P, Lasarte JJ, Zabaleta A, et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol 2003; 77: 10862-71.
94. +) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002; 76: 5062-70.